Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of 'systemic steatosis'.

@article{Balasubramanyam2004PathophysiologyOD,
  title={Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of 'systemic steatosis'.},
  author={Ashok Balasubramanyam and Rajagopal V. Sekhar and Farook Jahoor and Peter J. H. Jones and Henry J. Pownall},
  journal={Current opinion in lipidology},
  year={2004},
  volume={15 1},
  pages={
          59-67
        }
}
PURPOSE OF REVIEW This review addresses a syndrome of dyslipidemia and lipodystrophy that has emerged in HIV-infected patients receiving highly active antiretroviral therapy (HAART). The term 'HIV/HAART associated dyslipidemic lipodystrophy (HADL)' describes this syndrome. Although HAART increases patient survival rates, their increased longevity and dyslipidemias place them at risk for cardiovascular disease. Identification of rationally based therapies requires an understanding of the… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

Patients with immunodeficiency.

  • The Medical clinics of North America
  • 2013

Similar Papers